Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.
about
Temperament type specific metabolite profiles of the prefrontal cortex and serum in cattleIntegrative biological analysis for neuropsychopharmacologyMetabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.Development and in silico evaluation of large-scale metabolite identification methods using functional group detection for metabolomics.Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.Acute Exposure to Pacific Ciguatoxin Reduces Electroencephalogram Activity and Disrupts Neurotransmitter Metabolic Pathways in Motor Cortex.The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairmentTargeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD).Progress in Metabolomics Standardisation and its Significance in Future Clinical Laboratory MedicineStability of energy metabolites-An often overlooked issue in metabolomics studies: A review.Developing proteomic biomarkers for bladder cancer: towards clinical application.Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences.Epithelial-to-mesenchymal transition involves triacylglycerol accumulation in DU145 prostate cancer cells.Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?Lipid Profiling of In Vitro Cell Models of Adipogenic Differentiation: Relationships With Mouse Adipose Tissues.Short overview on metabolomic approach and redox changes in psychiatric disorders.Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease.The Role of Metabolomics in Brain Metabolism ResearchIdentification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics.Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease.Serum Metabonomics of Mild Acute Pancreatitis.Analysis of Potential Amino Acid Biomarkers in Brain Tissue and the Effect of Galangin on Cerebral Ischemia.Fearful dogs have increased plasma glutamine and γ-glutamyl glutamine
P2860
Q21090552-F183EEB1-9979-4F85-AF28-F5A192A87D3EQ28392635-E113A0BF-F355-4DBE-A98F-B869D5D2692DQ33746846-C89AA349-9FD1-4D07-AAFF-36C835F4451DQ33959026-BBC4DB81-6D91-4F7D-8017-BDD92880D5FBQ36043383-AE847B48-3E65-448D-A3FB-3981813D157FQ36129018-FAC94487-3A83-4552-A4C9-60D413D0118BQ36428387-81C65F85-CEDC-4E47-A106-A789FAC31A26Q36713818-5FD5B709-DE9E-4071-A95B-6756686C18D3Q37615997-9DF65D88-9A87-4DE1-8FDE-C3C17D31D7B0Q38469946-CC0552BA-74BF-48B3-A42B-5946FCA73D63Q38511509-4247A75A-E0E6-472A-B942-752A5E8DF69FQ38803730-FCC01596-50A2-49AE-A550-3D1CAFEC37D2Q38827404-E66C5506-4C74-4AED-8471-F151851304D5Q38922839-F22E1B0A-294E-43C9-AFC2-FF4E4850A578Q39972407-42B26E8F-705E-4B48-87FC-1547744EDB94Q41791000-162261A4-6E65-4F5C-BA58-9481088045C9Q41934251-3CF7E5A3-3073-4792-8C3A-FBD10BB5211EQ42103077-A20E3E5C-F5F6-44D3-9C06-4686B710F9BFQ46246621-06CD20A1-3353-4F76-A357-A78CCE3BEACCQ50041775-ED662C1F-4A55-41B4-831F-49FC61EC992BQ50558955-156767D1-F22C-4B45-928D-D999BA08E315Q51383518-8BBA7317-6D29-4322-9E90-71D677C249D8Q58107332-9ADDCCD1-0F87-4A98-AA7F-9543C5494FEA
P2860
Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mass spectrometry strategies f ...... neurology, and neuro-oncology.
@en
type
label
Mass spectrometry strategies f ...... neurology, and neuro-oncology.
@en
prefLabel
Mass spectrometry strategies f ...... neurology, and neuro-oncology.
@en
P2860
P356
P1476
Mass spectrometry strategies f ...... neurology, and neuro-oncology.
@en
P2093
Paul L Wood
P2860
P2888
P356
10.1038/NPP.2013.167
P407
P577
2013-07-11T00:00:00Z
P6179
1003049581